Cancers | |
Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer | |
Ke Wan1  Toshio Shimokawa1  Hirokazu Nagai2  Ibu Matsuzaki2  Yuichi Kinoshita2  Reiko Ashida3  Masahiro Itonaga3  Yasunobu Yamashita3  Tomoya Emori3  Keiichi Hatamaru3  Takashi Tamura3  Yuudai Kayama3  Masayuki Kitano3  Yuki Kawaji3  Hiroki Yamaue4  Manabu Kawai4  Shin-Ichi Murata4  | |
[1] Clinical Study Support Center, Wakayama Medical University, Wakayama 641-0012, Japan;Department of Human Pathology, Wakayama Medical University, Wakayama 641-0012, Japan;Second Department of Internal Medicine, Wakayama Medical University, Wakayama 641-0012, Japan;Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama 641-0012, Japan; | |
关键词: Kras; pancreatic ductal adenocarcinoma; pancreatic cancer; gemcitabine and nab-paclitaxel; EUS-FNA; liquid-based cytology; | |
DOI : 10.3390/cancers14030551 | |
来源: DOAJ |
【 摘 要 】
Background: Although several molecular analyses have shown that the Kras gene status is related to long-term survival of patients with pancreatic ductal adenocarcinoma (PDAC), the results remain controversial. Here, we examined the Kras gene status in a cohort of unresectable PDAC patients who underwent first-line therapy with gemcitabine and nab-paclitaxel (GA) and assessed differences in chemotherapy responses and survival. Methods: Patients with a histological diagnosis of PDAC (based on EUS-guided fine-needle aspiration) from 2017 to 2019 were enrolled. Tumor genomic DNA was extracted from residual liquid-based cytology specimens and Kras mutations were assessed using the quenching probe method. The relationships between the Kras status and progression-free survival (PFS) and overall survival (OS) were assessed. Results: Of the 110 patients analyzed, 15 had wild-type Kras. Those with the wild-type gene showed significantly longer PFS and OS than those with mutant Kras (6.9/5.3 months (p = 0.044) vs. 19.9/11.8 months (p = 0.037), respectively). Multivariate analyses identified wild-type Kras as a significant independent factor associated with longer PFS and OS (HR = 0.53 (p = 0.045) and HR = 0.35 (p = 0.007), respectively). Conclusions: The analysis of the Kras gene status could be used to predict therapeutic responses to GA and prognosis in unresectable PDAC patients.
【 授权许可】
Unknown